Cannabis Stocks on Fire: Why the Momentum Could Skyrocket
How a single video has re-ignited a surge in cannabis equities—and what that means for investors
In the last few days, cannabis stocks have broken out of the doldrums with surprising volatility and upside. What looked like a muted sector has suddenly caught fire, with names like Tilray (TLRY.O / TLRY), Canopy Growth (CGC / WEED.TO), Cronos Group (CRON.TO / CRON), Aurora Cannabis (ACB / ACB.TO) and ETFs such as MSOS (AdvisorShares Pure U.S. Cannabis ETF) leading the charge. The sector, classified broadly under healthcare / cannabis / biotech, is now under the spotlight — and for good reason.
It all traces back to a video posted by former President Donald Trump, endorsing cannabidiol (CBD) as a tool for senior healthcare, suggesting that it could help reduce disease progression and serve as an alternative to conventional medications. That single post sent a ripple through markets — MSOS jumped over 20 % in premarket trading.
Among individual stocks, the moves have been dramatic. Tilray (TLRY.O) surged nearly 20–40 %, riding the wave of investor enthusiasm. Canopy Growth (CGC / WEED.TO) climbed about 20 %, while Cronos (CRON / CRON.TO) and Aurora (ACB / ACB.TO) both added around 13 % each to their gains. Even Innovative Industrial Properties (IIPR) — a REIT that owns cannabis real estate — managed modest gains, riding the broader lift.
What’s driving this sudden rally? The market has long waited for a regulatory catalyst, and this appears to be it. The suggestion that marijuana might be reclassified from its current Schedule I status at the federal level in the U.S. has energized the narrative. Rescheduling could erase or ease tax burdens (like Section 280E) that currently squeeze cannabis companies, potentially unlocking more capital access and improving profitability across the sector.
But this isn’t just about policy bets. Many of these names are highly volatile, speculative plays in the alternative / specialty / cannabis sector. Their valuations are fragile, and they depend heavily on sentiment, political winds, and regulatory clarity. The flip side? If expectations get ahead of reality, corrections could be sharp — and sudden.
For investors eyeing this trend, here’s where risk and opportunity intersect. The MSOS ETF offers diversified exposure to U.S.-listed cannabis plays, reducing the single-stock risk. Meanwhile, names like Tilray, Canopy, Cronos, and Aurora carry higher upside (and higher danger) depending on how legalization and regulation evolve.
If you’re willing to take the gamble, timing matters. The early phase of a rally like this — with strong volume and momentum — can reward bold entries. But it also demands vigilant risk control: setting stop-losses, managing position sizes, and being ready to act when the narrative shifts.
This moment is electric for the cannabis industry. Reclassification, federal reform, and renewed investor interest are converging. But behind the headlines lies a high-wire act: gains are possible, but losses loom for those unprepared.